SCHEDULE: MAK Capital Boosts Autolus Therapeutics Stake to 10.1%

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman collectively reported a 10.1% beneficial ownership in Autolus Therapeutics plc.

Summary

• MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The Reporting Persons beneficially own 26,887,508 American Depositary Shares ("ADS") of Autolus Therapeutics plc, with each ADS representing one ordinary share.
• This ownership represents 10.1% of the total ordinary shares outstanding.
• The calculation of the percentage is based on 266,143,286 ordinary shares (including shares in the form of ADS) outstanding as of November 11, 2025, as reported by Autolus Therapeutics plc in its Quarterly Report on Form 10-Q filed on November 12, 2025.
• The Reporting Persons share both voting and dispositive power over all 26,887,508 shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment, which is generally viewed positively as a vote of confidence, but it does not provide operational or financial performance details.

Positives

• The disclosure of a significant 10.1% stake by an institutional investor group like MAK Capital can be interpreted as a vote of confidence in Autolus Therapeutics plc's long-term prospects.
• Increased transparency regarding major shareholders provides clarity to the market.

Risks

• No specific risks are mentioned in this beneficial ownership filing. The Reporting Persons certified that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future performance or strategy.

Management Comments

• The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Increased institutional ownership by a fund like MAK Capital can signal growing investor interest or confidence in the biotechnology sector, particularly for companies like Autolus Therapeutics plc which are typically in the development phase and rely on investor capital. Such a significant stake can also enhance the company's visibility within the institutional investment community.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive signal, potentially increasing confidence and liquidity in the stock.
• Company Management: Awareness of a large, passive shareholder, but no direct impact on operations or strategy is implied by a 13G filing.

Next Steps

• No specific future actions or milestones are mentioned in this beneficial ownership filing.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant, passive stake by MAK Capital in Autolus Therapeutics plc, which is generally a positive signal of institutional confidence. However, as a passive ownership disclosure, it provides no new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates or financial results from Autolus Therapeutics plc to make a more informed decision.

Keywords

Autolus Therapeutics, MAK Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, ADS, Ordinary Shares, Biotechnology, Healthcare